GSK has pulled off a major coup, replacing outgoing chief science officer Patrick Vallance with Calico and former Roche/Genentech whizz, Dr Hal Barron with a bumper pay package that could b
Roche’s Tecentriq has been added to the new-look Cancer Drugs Fund for bladder cancer patients, making it the latest in a recent flurry of drugs to be put on the managed access fund.
Roche has withdrawn a cancer drug from Greece, saying that a series of government-imposed price discounts have made it impossible to market the drug there.
